- Conditions
- Breast Cancer
- Interventions
- paclitaxel, valspodar
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Stanford, California • Flemington, New Jersey + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- bexarotene
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- lapatinib ditosylate, everolimus, capecitabine, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- Oana Danciu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
- Conditions
- Breast Cancer, Tumor, Breast
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Breastcancer, Breast Neoplasm
- Interventions
- SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b
- Biological · Drug
- Lead sponsor
- BriaCell Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Santa Rosa, California • Plantation, Florida • Wichita, Kansas + 2 more
- Conditions
- Breast Cancer
- Interventions
- aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- Up to 64 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- sorafenib tosylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative
- Interventions
- Atezolizumab, Cobimetinib, Idasanutlin
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
- Interventions
- Ixabepilone, Capecitabine, Motesanib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Breast Cancer
- Interventions
- LY2523355, ixabepilone, pegfilgrastim, filgrastim
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 12
- States / cities
- Fort Myers, Florida • Pensacola, Florida • Gainesville, Georgia + 9 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 79
- States / cities
- Tucson, Arizona • Corona, California • Duarte, California + 63 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody BrE-3
- Biological · Procedure · Radiation
- Lead sponsor
- Cancer Research Institute of Contra Costa
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 2
- States / cities
- San Francisco, California • Aurora, Colorado
- Conditions
- Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Interventions
- Gemcitabine Hydrochloride, Tipifarnib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 32
- States / cities
- Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- ixabepilone, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 5
- States / cities
- Farmington, Connecticut • Albany, New York • New York, New York + 1 more
- Conditions
- Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- dietary intervention, nutritional support, laboratory biomarker analysis
- Dietary Supplement · Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Rochester, Minnesota
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Interventions
- NS-9 [Poly I: Poly C]
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Houston, Texas
- Conditions
- Triple Negative Breast Cancer, Residual Disease
- Interventions
- Tetrathiomolybdate, Capecitabine, Pembrolizumab
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Lebanon, New Hampshire • New York, New York
- Conditions
- Breast Cancer
- Interventions
- counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Solid Tumors, CNS Tumors
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more